FILTER

FILTERED INTERVIEW RESULTS

Simao Antunes

GENERAL MANAGER - SOUTH AMERICA, HOFMANN ENGINEERING
"We are constantly looking at what are the current performances and failure modes of the OEM product and with our own design department, we carry out investigations and engineering analysis to come up with better features to improve our products."

Réjean Girard

CEO AND GENERAL MANAGER, IOS SERVICES GEOSCIENTIFIQUES
“To be able to grow, you need to offer something to the world that nobody else has, which we believe we are doing with our services.”

Raphaël Pelletier

ACCOUNT EXECUTIVE - AMERICAS, HOWDEN
“Mining activity in Canada contributes to Howden’s product road map and acts as a compass for its future developments.”

John McCluskey

PRESIDENT AND CEO, ALAMO GOLDS
Alamos Gold updates GBR on its Canadian and Mexican assets.

Ross Sherlock

DIRECTOR OF MERC AND METAL EARTH, CHAIR IN EXPLORATION TARGETING, LAURENTIAN UNIVERSITY
Laurentian University details the activities of MERC and Metal Earth in geological mapping.

Asimwe Kabunga

CHAIRMAN, LINDIAN RESOURCES
Lindian Resources is extending its portfolio of assets in Africa from bauxite in Guinea to rare earths in Malawi.

Guy Goulet & Manuel Rodríguez-Mariátegui

CEO AND EXECUTIVE DIRECTOR, CERRO DE PASCO RESOURCES
"Cerro de Pasco Resources plans to acquire more operating mines to integrate into its portfolio to supplement its work on tailings and stockpiles."

Errol Smart

CEO, ORION MINERALS
Orion Minerals outlines its strategy for developing copper and zinc projects in South Africa.

Bernard Kaninda

REGIONAL DIRECTOR AFRICA, MAXAM
Maxam describes growing demand for its explosives across West Africa.

Lisa Davis

CEO, PEARTREE SECURITIES
Pear Tree Securities speaks to GBR of the role of flow-through financing for mining.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS